Mediolanum licences Apeptico’s TNF p... Viennese Apeptico Forschung und Entwicklung GmbH and Milan-based Mediolanum Farmaceutici S.p.A. have signed a research & development cooperation and license agreement for Apeptico’s compound so … more ➔
A fresh take on biotech?For the second time, biotech communication start-up Labiotech hosted its event LBRefresh, this year in Paris, France. Participants enjoyed panel discussions, a start-up battle and intimate fireside chats… more ➔
Bioplastics industry grapples with ignoran...EU consumers have minor knowledge on bioplastics but unrealistically high expectations that can not be fulfilled, researchers said at 11th European Bioplastics Conference in Berlin. more ➔
Carbios tackles marine litteringFrench Carbios has presented a process that depolymerises one of the most common non-recycled plastics polluting the oceans. more ➔
Neovacs teams up with 3PFrench immunotherapy expert Neovacs has teamed up with CDMO 3P Biopharmaceuticals for the manufacture of interferon alpha with recently licensed technology. more ➔
Kymab raises €94m for mAb pipelineUK-based biopharma group Kymab has brought a new backer from China on board. With the help from ORI Healthcare Fund, Kymab secured a US$100m Series C financing. more ➔
Proteros inks US$167m oncology pact with M...Proteros has expanded its epigenetic drug discovery services for MSD. Just one year after having signed a first R&D pact, the computational chemistry firm inked a second contract in oncolog … more ➔
Running made by biotechAdidas has presented the world’s first lightweight racing shoe made by recombinantly produced silk fibers. more ➔
Medigene offers neoantigen-specific TCRs Until mid-October, cancer immunotherapy play Medigene AG was a pure drug developer. With a potential US$1bn TCR-contract manufacturing deal with Bluebird Bio, it widened its business focus. Now, the … more ➔
Roche ramps up immunotherapy R&DSwiss cancer meds world market leader Roche intensifies its focus on translational research to broaden the scope of cancer immunotherapies. more ➔
